Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a single-center, double blind, randomized, placebo-controlled, parallel group study of bear bile pill, as add-on therapy in MDD patients conducted in Shang Hai Mental Health Center. The purpose of this study is to determine the efficacy and safety of bear bile pill in reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate response to current antidepressant therapy. Following a screening period, subjects who meet the entry criteria will be randomized to treated with either placebo or 450mg bear bile pill three times daily for 8 weeks.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| bear bile pill | Experimental | Patients randomized to the bear bile pill arm will receive treatment with 15 pills, three times daily of bear bile pill (1350mg per day) plus on-going antidepressant therapy (SSRI/SNRI). |
|
| placebo | Placebo Comparator | Patients randomized to the placebo arm will receive 15 pills, three times daily of placebo plus on-going antidepressant therapy (SSRI/SNRI). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| bear bile pill | Drug | Bear bile pill (15 pills) taken orally three times a day after meals with water. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in the total Montgomery-Asberg Depression Rating Scale (MADRS) score between randomization and end of study. | The main objective is to explore whether bear bile pill add on SSRI or SNRI will improve the MDD symptoms after 8 weeks of treatment, and investigators assess the scale at baseline and week 1, 2, 4, 8. | assessed from baseline to week 8(end of study) |
| Measure | Description | Time Frame |
|---|---|---|
| Effective treatment | effectivity:MADRS or HAMD reduction ratio ≥50% reductive ratio: [(Baseline score- Endpoint score)/Baseline score]×100% | assessed from baseline to week 8 (end of study) |
| Clinical remission rate |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jing jing Huang | Contact | +86 021 34773308 | jjhuang_att@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Jingjing huang | Shanghai Mental Health Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Jing jing Huang | Shanghai | China |
|
Not provided
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| placebo | Drug | Placebo(15 pills) taken orally three times a day after meals with water. |
|
patients who are in remission at the end of the study will be summarized by treatment group, MADRS score ≤12 or HAMD-17≤7.
| assessed from baseline to week 8 (end of study) |
| The Montgomery-Asberg Depression Rating Scale (MADRS) reduction ratio | MADRS reduction ratio were used to evaluate the effectiveness of the treatment,and investigators assess the scale at baseline and week 1, 2, 4, 8. | assessed from baseline to week 8 (end of study) |
| The Hamilton Depression Rating Scale (HAM-D17) reduction ratio | the Hamilton Depression Rating Scale reduction ratio were used to evaluate the effectiveness of the treatment,and investigators assess the scale at baseline and week 1, 2, 4, 8. | assessed from baseline to week 8 (end of study) |
| change in the total score of the Hamilton Anxiety Scale(HAMA) | assessed from baseline to week 8 (end of study) |
| change in total score of the Clinical Global Impression-Severity (CGI-S) scale. | assessed from baseline to week 8 (end of study) |
| change in total score of the Clinical Global Impression-Improvement (CGI-I) scale. | assessed from baseline to week 8 (end of study) |